Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Of the top news articles, Vertex Pharmaceuticals' suzetrigine garnered much attention as it's a promising new class of pain ...

Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...

This was the stock's fourth consecutive day of gains.

T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.

Technological Advancements : Ongoing innovations in gene delivery methods, such as the development of next-generation viral and non-viral vectors, are expected to drive substantial growth in the gene ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA – Research Report), ...

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.